| 0.7198 -0.031 (-4.18%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.94 | 1-year : | 1.05 |
| Resists | First : | 0.8 | Second : | 0.9 |
| Pivot price | 0.75 |
|||
| Supports | First : | 0.64 | Second : | 0.53 |
| MAs | MA(5) : | 0.76 |
MA(20) : | 0.73 |
| MA(100) : | 0.76 |
MA(250) : | 0.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 42 |
D(3) : | 49.8 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 1.15 | Low : | 0.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NMTC ] has closed above bottom band by 35.0%. Bollinger Bands are 13.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.79 | 0.79 - 0.8 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.71 - 0.72 | 0.72 - 0.73 |
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Thu, 12 Mar 2026
Neuroone medical director Christianson sells $10k in NMTC stock - Investing.com Nigeria
Thu, 12 Mar 2026
NeuroOne (NASDAQ: NMTC) officer sells 13,720 shares around $0.80 - Stock Titan
Thu, 12 Mar 2026
NMTC: Guiding for $10.5M+ revenue in 2026, driven by novel devices and expanding partnerships - TradingView
Thu, 12 Mar 2026
NMTC: Revenue set to exceed $10.5M in 2026, driven by device launches and strategic partnerships - TradingView
Tue, 03 Mar 2026
NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 51 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 24.6 (%) |
| Shares Short | 207 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | -58.3 % |
| Operating Margin | -59.1 % |
| Return on Assets (ttm) | -63.5 % |
| Return on Equity (ttm) | -146.3 % |
| Qtrly Rev. Growth | -11.7 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4 |
| PEG Ratio | 0 |
| Price to Book value | 5.53 |
| Price to Sales | 3.1 |
| Price to Cash Flow | -5.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|